Cellectis (CLLS) Income from Non-Controlling Interests (2015 - 2025)
Cellectis' (CLLS) quarterly Income from Non-Controlling Interests came in at -$539.0 million in Q3 2025, up 17.33% year-on-year from -$459.4 million in Q3 2024, and down 182.67% quarter-over-quarter from $652.0 million in Q4 2024.
Cellectis (CLLS) Income from Non-Controlling Interests (2015 - 2025) Analysis & Trends
Cellectis' Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at -$539.0 million for Q3 2025.
- On a quarterly basis, Income from Non-Controlling Interests rose 17.33% year-over-year to -$539.0 million in Q3 2025; TTM through Sep 2025 was -$539.0 million, a 17.33% increase from a year earlier, with the FY2023 full-year figure at -$7.4 million, up 6.46% from the prior year.
- Income from Non-Controlling Interests fell to -$539.0 million in Q3 2025 per CLLS's latest filing, from $652.0 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $652.0 million in Q4 2024 and bottomed at -$652.0 million in Q3 2024.
- The 5-year median for Income from Non-Controlling Interests is -$2.8 million (2022), against an average of -$43.4 million.
- Across the five-year window, Income from Non-Controlling Interests soared 129.92% in 2022 and plunged 1075.1% in 2023, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$3.1 million in 2021, then soared by 43.45% to -$1.7 million in 2022, then plunged by 182.91% to -$4.9 million in 2023, then surged by 13314.43% to $652.0 million in 2024, then sank by 182.67% to -$539.0 million in 2025.
- Per Business Quant, the three latest CLLS Income from Non-Controlling Interests figures stand at -$539.0 million (Q3 2025), $652.0 million (Q4 2024), and -$652.0 million (Q3 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -539.00 Mn |
| Dec 31, 2024 | 652.00 Mn |
| Sep 30, 2024 | -652.00 Mn |
| Jun 30, 2023 | -4.93 Mn |
| Mar 31, 2023 | -2.45 Mn |
| Dec 31, 2022 | -1.74 Mn |
| Sep 30, 2022 | -2.80 Mn |
| Jun 30, 2022 | 506,000.00 |
| Mar 31, 2022 | -2.85 Mn |
| Dec 31, 2021 | -3.08 Mn |
| Sep 30, 2021 | -2.66 Mn |
| Jun 30, 2021 | -1.69 Mn |
| Mar 31, 2021 | -3.48 Mn |
| Dec 31, 2020 | -6.12 Mn |
| Sep 30, 2020 | -3.31 Mn |
| Jun 30, 2020 | -3.59 Mn |
| Mar 31, 2020 | -3.48 Mn |
| Dec 31, 2019 | -3.95 Mn |
| Sep 30, 2019 | -3.49 Mn |
| Jun 30, 2019 | -3.19 Mn |